https://news.medxy.ai/zh/acute-kidney-injury-markers/Medxy AIzh2026-09-18T11:53:49-07:00重症患者急性肾损伤新型生物标志物：证据图谱全景解读 https://news.medxy.ai/ja/75094-2/Medxy AIja2026-09-18T11:53:27-07:00重症患者における急性腎障害の新規バイオマーカー https://news.medxy.ai/vi/75092-2/Medxy AIvi2026-09-18T11:53:07-07:00Các dấu ấn sinh học mới đối với tổn thương thận cấp ở bệnh nhân nguy kịch https://news.medxy.ai/unlocking-the-potential-of-novel-biomarkers-for-acute-kidney-injury-in-the-critically-ill-a-comprehensive-evidence-mapping/Medxy AIen2026-09-18T11:52:49-07:00Unlocking the Potential of Novel Biomarkers for Acute Kidney Injury in the Critically Ill: A Comprehensive Evidence Mapping https://news.medxy.ai/zh/value-based-payment-impact/Medxy AIzh2026-09-18T11:52:04-07:00基于相对价值单位计酬对急诊医师绩效与运营结局影响的评估 https://news.medxy.ai/ja/rvu-based-payments-impact/Medxy AIja2026-09-18T11:51:47-07:00救急医師のRVUベース報酬は現場を変えるか――生産性と運営指標への影響を検証 https://news.medxy.ai/vi/rvu-impact-efficiency/Medxy AIvi2026-09-18T11:51:23-07:00Chi trả theo RVU ảnh hưởng thế nào đến hiệu suất bác sĩ cấp cứu và kết quả vận hành? https://news.medxy.ai/evaluating-the-impact-of-relative-value-unit-based-compensation-on-emergency-physician-performance-and-operational-outcomes/Medxy AIen2026-09-18T11:51:02-07:00Evaluating the Impact of Relative Value Unit-Based Compensation on Emergency Physician Performance and Operational Outcomes https://news.medxy.ai/ja/smart-bedside-station-factors/Medxy AIja2026-09-18T11:50:19-07:00入院患者のSmart Bedside Station利用を左右する要因とは：UTAUTに基づく質的研究 https://news.medxy.ai/vi/smart-bed-system-factors/Medxy AIvi2026-09-18T11:50:00-07:00Các yếu tố thúc đẩy và rào cản khi sử dụng hệ thống Trạm đầu giường thông minh ở người bệnh nội trú: Nghiên cứu định tính dựa trên UTAUT https://news.medxy.ai/facilitators-and-barriers-of-using-smart-bedside-station-systems-among-hospitalized-patients-a-qualitative-study-based-on-utaut/Medxy AIen2026-09-18T11:49:39-07:00Facilitators and Barriers of Using Smart Bedside Station Systems Among Hospitalized Patients: A Qualitative Study Based on UTAUT https://news.medxy.ai/zh/cancer-palliative-care/Medxy AIzh2026-09-18T11:49:01-07:00优化癌症患者临终关怀转衔：来自多中心定性与定量证据的启示 https://news.medxy.ai/ja/75063-2/Medxy AIja2026-09-18T11:48:41-07:00がん患者のターミナルケアにおける移行の最適化 https://news.medxy.ai/vi/75061-2/Medxy AIvi2026-09-18T11:48:17-07:00Tối ưu hóa quá trình chuyển tiếp sang chăm sóc cuối đời cho bệnh nhân ung thư https://news.medxy.ai/optimizing-palliative-care-for-effective-hospice-transitions-in-cancer-patients-insights-from-multicenter-qualitative-and-quantitative-evidence/Medxy AIen2026-09-18T11:47:54-07:00Optimizing Palliative Care for Effective Hospice Transitions in Cancer Patients: Insights from Multicenter Qualitative and Quantitative Evidence https://news.medxy.ai/ja/ckd-anemia-guide/Medxy AIja2026-09-18T11:46:56-07:00CKDの貧血に関するKDIGO 2026：臨床医のための主要推奨と実践ガイド https://news.medxy.ai/vi/anemia-ckd-kdigo-2026/Medxy AIvi2026-09-18T11:46:23-07:00Thiếu máu trong CKD theo KDIGO 2026: các khuyến nghị cốt lõi và hướng dẫn thực hành cho lâm sàng viên https://news.medxy.ai/zh/ckd-anemia-guidelines/Medxy AIzh2026-09-18T11:45:50-07:00KDIGO 2026 CKD 贫血指南要点：临床医师实用解读 https://news.medxy.ai/kdigo-2026-on-anemia-in-ckd-key-recommendations-and-practical-guidance-for-clinicians/Medxy AIen2026-09-18T11:45:23-07:00KDIGO 2026 on Anemia in CKD: Key Recommendations and Practical Guidance for Clinicians https://news.medxy.ai/zh/sickle-cell-stem-cell-mobilization/Medxy AIzh2026-09-18T11:44:20-07:00镰状细胞病自体备用干细胞动员优化：GCSF联合plerixafor的应用及其对基因治疗的启示 https://news.medxy.ai/ja/75038-2/Medxy AIja2026-09-18T11:44:02-07:00鎌状赤血球症における自家幹細胞動員の最適化：G-CSFとプレリキサホールの併用および遺伝子治療への示唆 https://news.medxy.ai/vi/stem-cell-mobilization/Medxy AIvi2026-09-18T11:43:43-07:00Tối ưu hóa huy động tế bào gốc tự thân dự phòng bằng GCSF và plerixafor trong bệnh hồng cầu hình liềm: Hàm ý cho liệu pháp gen https://news.medxy.ai/optimizing-autologous-stem-cell-backup-mobilization-with-gcsf-and-plerixafor-in-sickle-cell-disease-implications-for-gene-therapy/Medxy AIen2026-09-18T11:43:23-07:00Optimizing Autologous Stem Cell Backup Mobilization with GCSF and Plerixafor in Sickle Cell Disease: Implications for Gene Therapy https://news.medxy.ai/zh/oral-ixazomib-pomalidomide-dexamethasone/Medxy AIzh2026-09-18T11:42:42-07:00全口服伊沙佐米、泊马度胺联合地塞米松治疗三药类暴露多发性骨髓瘤的疗效与安全性：来自II期研究的启示 https://news.medxy.ai/ja/oral-ixazomib-therapy/Medxy AIja2026-09-18T11:42:22-07:00三剤クラス曝露多発性骨髄腫に対する全経口イキサゾミブ・ポマリドミド・デキサメタゾン療法の有効性と安全性：第II相試験からの示唆 https://news.medxy.ai/vi/ixazomib-pomalidomide-dexamethasone/Medxy AIvi2026-09-18T11:42:04-07:00Hiệu quả và tính an toàn của phác đồ uống hoàn toàn ixazomib, pomalidomide và dexamethasone ở đa u tủy xương đã phơi nhiễm với ba nhóm thuốc: Nhận định từ nghiên cứu giai đoạn II https://news.medxy.ai/efficacy-and-safety-of-all-oral-ixazomib-pomalidomide-and-dexamethasone-in-triple-class-exposed-multiple-myeloma-insights-from-a-phase-ii-study/Medxy AIen2026-09-18T11:41:43-07:00Efficacy and Safety of All-Oral Ixazomib, Pomalidomide, and Dexamethasone in Triple-Class Exposed Multiple Myeloma: Insights from a Phase II Study https://news.medxy.ai/zh/bcr-abl1-treatment/Medxy AIzh2026-09-18T11:40:53-07:00阿西米尼为 BCR::ABL1 T315I 突变型慢性髓性白血病提供有力治疗选择：Ⅰ期试验最终结果 https://news.medxy.ai/ja/75013-2/Medxy AIja2026-09-18T11:40:36-07:00アシミニブはBCR::ABL1 T315I変異型慢性骨髄性白血病に対する有力な治療選択肢となる：第I相試験の最終結果 https://news.medxy.ai/vi/75011-2/Medxy AIvi2026-09-18T11:40:15-07:00Asciminib mang lại một lựa chọn điều trị hiệu quả cho bệnh bạch cầu tủy mạn tính có đột biến BCR::ABL1 T315I https://news.medxy.ai/asciminib-as-a-robust-treatment-option-for-bcrabl1-t315i-mutated-chronic-myeloid-leukemia-final-phase-1-trial-outcomes/Medxy AIen2026-09-18T11:39:56-07:00Asciminib as a Robust Treatment Option for BCR::ABL1 T315I-Mutated Chronic Myeloid Leukemia: Final Phase 1 Trial Outcomes https://news.medxy.ai/zh/nk-cells-ifn-activation/Medxy AIzh2026-09-18T11:39:11-07:00激活Ⅰ型干扰素的 NK 细胞：真性红细胞增多症免疫治疗的新策略 https://news.medxy.ai/ja/nk-cell-activation-therapy/Medxy AIja2026-09-18T11:38:50-07:00第I型インターフェロンで活性化されるNK細胞を活用する：真性多血症に対する新たな免疫治療戦略 https://news.medxy.ai/vi/nk-cell-therapy/Medxy AIvi2026-09-18T11:38:23-07:00Khai thác tế bào NK được hoạt hóa bởi interferon type I: hướng miễn dịch trị liệu mới cho đa hồng cầu nguyên phát https://news.medxy.ai/harnessing-type-i-interferon-activated-nk-cells-a-novel-immunotherapeutic-approach-to-polycythemia-vera/Medxy AIen2026-09-18T11:38:01-07:00Harnessing Type-I Interferon-Activated NK Cells: A Novel Immunotherapeutic Approach to Polycythemia Vera https://news.medxy.ai/zh/eosinophil-count-asthma/Medxy AIzh2026-09-18T11:37:14-07:00Rademikibart与中重度哮喘中的嗜酸性粒细胞计数：来自2b期随机试验的启示 https://news.medxy.ai/ja/rademikibart-eosinophils-asthma-2/Medxy AIja2026-09-18T11:36:53-07:00中等症から重症喘息におけるRademikibartと好酸球数：第2b相無作為化試験からの知見 https://news.medxy.ai/vi/rademikibart-eosinophils-asthma/Medxy AIvi2026-09-18T11:36:29-07:00Rademikibart và số lượng bạch cầu ái toan trong hen phế quản mức độ trung bình đến nặng: Góc nhìn từ thử nghiệm ngẫu nhiên pha 2b https://news.medxy.ai/rademikibart-and-eosinophil-counts-in-moderate-to-severe-asthma-insights-from-a-phase-2b-randomized-trial/Medxy AIen2026-09-18T11:36:05-07:00Rademikibart and Eosinophil Counts in Moderate-to-Severe Asthma: Insights from a Phase 2b Randomized Trial https://news.medxy.ai/zh/pseudomonas-subtypes-2/Medxy AIzh2026-09-18T11:35:17-07:00解读铜绿假单胞菌亚型：支气管扩张症临床差异的意义 https://news.medxy.ai/ja/pseudomonas-subtypes/Medxy AIja2026-09-18T11:34:59-07:00気管支拡張症における緑膿菌サブタイプを読み解く：臨床的不均一性への示唆 https://news.medxy.ai/vi/pseudomonas-aeruginosa-subgroups/Medxy AIvi2026-09-18T11:34:37-07:00Giải mã các phân nhóm <i>Pseudomonas aeruginosa</i>: Ý nghĩa đối với sự khác biệt lâm sàng trong giãn phế quản https://news.medxy.ai/decoding-pseudomonas-aeruginosa-subtypes-implications-for-clinical-variability-in-bronchiectasis/Medxy AIen2026-09-18T11:34:17-07:00Decoding Pseudomonas aeruginosa Subtypes: Implications for Clinical Variability in Bronchiectasis https://news.medxy.ai/zh/wavelight-lasik-outcomes/Medxy AIzh2026-09-18T11:33:33-07:00WaveLight Plus InnovEyes 射线追踪引导 LASIK 1 年结局：近视与近视性散光的精准屈光矫正 https://news.medxy.ai/ja/74992-2/Medxy AIja2026-09-18T11:33:11-07:00WaveLight Plus InnovEyes レイトレーシング・ガイデッドLASIKの1年後の成績 https://news.medxy.ai/vi/lasik-raytracing-results/Medxy AIvi2026-09-18T11:32:48-07:00Kết quả sau 1 năm của LASIK dẫn đường bằng ray-tracing WaveLight Plus InnovEyes: Hiệu chỉnh khúc xạ chính xác cho cận thị và loạn thị cận thị https://news.medxy.ai/one-year-outcomes-of-wavelight-plus-innoveyes-ray-tracing-guided-lasik-precision-refractive-correction-for-myopia-and-myopic-astigmatism/Medxy AIen2026-09-18T11:32:27-07:00One-Year Outcomes of WaveLight Plus InnovEyes Ray-Tracing-Guided LASIK: Precision Refractive Correction for Myopia and Myopic Astigmatism https://news.medxy.ai/zh/tonsil-pathology-checks/Medxy AIzh2026-09-18T11:31:36-07:00安全网医院常规扁桃体病理检查是否必要？低检出率支持风险分层策略 https://news.medxy.ai/ja/tonsil-pathology-utility/Medxy AIja2026-09-18T11:31:18-07:00安全網医療機関における定期的な扁桃病理検査の有用性を再考する：予期せぬ悪性腫瘍の検出率は低く、リスク層別化アプローチを支持 https://news.medxy.ai/vi/routine-tonsil-pathology/Medxy AIvi2026-09-18T11:30:57-07:00Giải phẫu bệnh amidan thường quy có thực sự cần thiết? Bằng chứng từ bệnh viện an sinh cho thấy tỷ lệ phát hiện ác tính bất ngờ rất thấp https://news.medxy.ai/evaluating-the-utility-of-routine-tonsil-pathology-in-a-safety-net-hospital-low-yield-of-unexpected-malignancies-supports-risk-stratified-approach/Medxy AIen2026-09-18T11:30:38-07:00Evaluating the Utility of Routine Tonsil Pathology in a Safety-Net Hospital: Low Yield of Unexpected Malignancies Supports Risk-Stratified Approach https://news.medxy.ai/zh/74983-2/Medxy AIzh2026-09-18T11:30:00-07:00早发型大肠癌的发病率仍在上升，且存在种族差异 https://news.medxy.ai/ja/colorectal-cancer-disparities/Medxy AIja2026-09-18T11:29:37-07:00大腸内視鏡検査は増えても続く若年発症大腸癌の増加と人種格差 https://news.medxy.ai/rising-early-onset-colorectal-cancer-and-persistent-racial-disparities-despite-increased-colonoscopy-use/Medxy AIen2026-09-18T11:28:47-07:00Rising Early-Onset Colorectal Cancer and Persistent Racial Disparities Despite Increased Colonoscopy Use https://news.medxy.ai/zh/imas-liver-transplant-2/Medxy AIzh2026-09-18T11:27:54-07:00综合肌肉-脂肪评分（IMAS）：提升肝移植后性别敏感性预后评估 https://news.medxy.ai/ja/imas-liver-transplant/Medxy AIja2026-09-18T11:27:36-07:00筋・脂肪を統合した新指標IMAS：肝移植後予後予測を性別に最適化する https://news.medxy.ai/vi/imas-liver-transplant-prognosis/Medxy AIvi2026-09-18T11:27:15-07:00IMAS: Điểm số cơ–mô mỡ tích hợp mở ra hướng tiên lượng sau ghép gan nhạy cảm với giới https://news.medxy.ai/integrative-muscle-adipose-score-imas-enhancing-sex-sensitive-prognostication-after-liver-transplantation/Medxy AIen2026-09-18T11:26:55-07:00Integrative Muscle-Adipose Score (IMAS): Enhancing Sex-Sensitive Prognostication After Liver Transplantation https://news.medxy.ai/zh/activate-quinolinic-acid/Medxy AIzh2026-09-18T11:26:19-07:00激活犬尿喹啉酸与脑肠轴：促进卒中恢复的新策略 https://news.medxy.ai/ja/stroke-recovery/Medxy AIja2026-09-18T11:25:58-07:00キヌレン酸と腸脳軸を活用した脳卒中回復促進 https://news.medxy.ai/vi/kynurenic-acid-stroke/Medxy AIvi2026-09-18T11:25:34-07:00Khai thác acid kynurenic và trục ruột-não để cải thiện hồi phục sau đột quỵ https://news.medxy.ai/harnessing-kynurenic-acid-and-the-gut-brain-axis-to-improve-stroke-recovery/Medxy AIen2026-09-18T11:25:14-07:00Harnessing Kynurenic Acid and the Gut-Brain Axis to Improve Stroke Recovery https://news.medxy.ai/zh/sglt2-stroke-recovery-2/Medxy AIzh2026-09-18T11:24:32-07:00糖尿病卒中患者接受血管内血栓切除术后使用SGLT2抑制剂可促进恢复：一项多中心回顾性研究 https://news.medxy.ai/ja/sglt2-stroke-recovery/Medxy AIja2026-09-18T11:24:13-07:00糖尿病性脳卒中患者の血管内血栓除去療法後回復をSGLT2阻害薬が後押し：多施設後ろ向き研究 https://news.medxy.ai/vi/sglt2-inhibitors-stroke-recovery/Medxy AIvi2026-09-18T11:23:52-07:00Chất ức chế SGLT2 giúp cải thiện hồi phục sau lấy huyết khối nội mạch ở bệnh nhân đột quỵ đái tháo đường: Nghiên cứu hồi cứu đa trung tâm https://news.medxy.ai/sglt2-inhibitors-enhance-recovery-after-endovascular-thrombectomy-in-diabetic-stroke-patients-a-multicenter-retrospective-study/Medxy AIen2026-09-18T11:23:31-07:00SGLT2 Inhibitors Enhance Recovery After Endovascular Thrombectomy in Diabetic Stroke Patients: A Multicenter Retrospective Study https://news.medxy.ai/zh/fenofibrate-diabetic-retinopathy-2/Medxy AIzh2026-09-18T11:22:45-07:00非诺贝特使用与2型糖尿病视力威胁性糖尿病视网膜病变风险降低：来自英国真实世界数据的启示 https://news.medxy.ai/ja/74942-2/Medxy AIja2026-09-18T11:22:28-07:00フェノフィブラートの使用と2型糖尿病における視力を脅かす糖尿病網膜症のリスク低下 https://news.medxy.ai/vi/fenofibrate-diabetic-retinopathy/Medxy AIvi2026-09-18T11:22:05-07:00Fenofibrate làm giảm nguy cơ bệnh võng mạc đái tháo đường đe dọa thị lực ở đái tháo đường type 2: Bằng chứng từ dữ liệu thực tế tại Vương quốc Anh https://news.medxy.ai/fenofibrate-use-and-reduced-risk-of-sight-threatening-diabetic-retinopathy-in-type-2-diabetes-insights-from-uk-real-world-data/Medxy AIen2026-09-18T11:21:44-07:00Fenofibrate Use and Reduced Risk of Sight-Threatening Diabetic Retinopathy in Type 2 Diabetes: Insights from UK Real-World Data https://news.medxy.ai/zh/ivus-pci-east-asia/Medxy AIzh2026-09-18T11:21:06-07:00IVUS引导PCI疗效为何存在地域差异？随机试验荟萃分析揭示东亚获益更显著 https://news.medxy.ai/ja/ivus-pci-regional%e5%b7%ae/Medxy AIja2026-09-18T11:20:46-07:00IVUSガイド下PCIの成績にみられる地域差：ランダム化試験メタ解析からの示唆 https://news.medxy.ai/vi/regional-pci-outcomes/Medxy AIvi2026-09-18T11:20:24-07:00Khác biệt theo khu vực về kết cục của PCI được hướng dẫn bằng IVUS so với hướng dẫn bằng chụp mạch: Góc nhìn từ phân tích gộp các thử nghiệm ngẫu nhiên https://news.medxy.ai/geographic-variability-in-outcomes-of-ivus-guided-versus-angiography-guided-pci-insights-from-a-meta-analysis-of-randomized-trials/Medxy AIen2026-09-18T11:20:04-07:00Geographic Variability in Outcomes of IVUS-Guided Versus Angiography-Guided PCI: Insights from a Meta-Analysis of Randomized Trials https://news.medxy.ai/zh/mybpc3-mutations/Medxy AIzh2026-09-18T11:19:09-07:00揭开隐匿性 MYBPC3 变异之谜：放大错剪接并致肥厚型心肌病 https://news.medxy.ai/ja/mybpc3-mutation-cardiomyopathy/Medxy AIja2026-09-18T11:18:47-07:00肥大型心筋症の鍵を握るMYBPC3潜在変異：ミススプライシング増幅の正体 https://news.medxy.ai/vi/74927-2/Medxy AIvi2026-09-18T11:18:25-07:00Các biến thể gen MYBPC3 có thể gây bệnh cơ tim phì đại https://news.medxy.ai/unveiling-a-cryptic-mybpc3-variant-amplifying-missplicing-in-hypertrophic-cardiomyopathy/Medxy AIen2026-09-18T11:18:01-07:00Unveiling a Cryptic MYBPC3 Variant Amplifying Missplicing in Hypertrophic Cardiomyopathy https://news.medxy.ai/zh/aml-preconditioning-options/Medxy AIzh2026-09-18T11:05:07-07:00AML清髓性预处理新选择：曲奥磺舒联合氟达拉滨在中年患者中的应用前景 https://news.medxy.ai/ja/treosulfan-fludarabine-aml/Medxy AIja2026-09-18T11:04:45-07:00AMLにおける骨髄破壊的 Treosulfan-Fludarabine 前処置を検証する：中年成人に有望な代替選択肢 https://news.medxy.ai/vi/myeloablative-conditioning-aml/Medxy AIvi2026-09-18T11:04:19-07:00Đánh giá phác đồ điều kiện hóa myeloablative treosulfan-fludarabine trong AML: một lựa chọn thay thế đầy hứa hẹn cho người trưởng thành trung niên https://news.medxy.ai/evaluating-myeloablative-treosulfan-fludarabine-conditioning-in-aml-a-promising-alternative-for-middle-aged-adults/Medxy AIen2026-09-18T11:03:57-07:00Evaluating Myeloablative Treosulfan-Fludarabine Conditioning in AML: A Promising Alternative for Middle-Aged Adults https://news.medxy.ai/zh/pediatric-bcell-receptor-maturation/Medxy AIzh2026-09-18T11:03:00-07:00儿科造血干细胞移植后B细胞受体库如何逐步成熟：早期免疫重建的新认识 https://news.medxy.ai/ja/74890-2/Medxy AIja2026-09-18T11:02:34-07:00小児における造血幹細胞移植後のB細胞受容体レパートリーの経時的成熟：早期免疫再構築に関する示唆 https://news.medxy.ai/vi/b-cell-receptor-development/Medxy AIvi2026-09-18T11:02:11-07:00Quá trình trưởng thành dần của kho thụ thể tế bào B sau ghép tế bào gốc tạo máu ở trẻ em: gợi ý về tái tạo miễn dịch giai đoạn sớm https://news.medxy.ai/gradual-maturation-of-the-b-cell-receptor-repertoire-after-pediatric-hematopoietic-stem-cell-transplantation-insights-into-early-immune-reconstitution/Medxy AIen2026-09-18T11:01:50-07:00Gradual Maturation of the B-Cell Receptor Repertoire After Pediatric Hematopoietic Stem Cell Transplantation: Insights into Early Immune Reconstitution https://news.medxy.ai/zh/bendamustine-t-cell-leukemia/Medxy AIzh2026-09-18T11:00:47-07:00苯达莫司汀作为高肿瘤负荷 T 细胞大颗粒淋巴细胞白血病的新型单药治疗：临床疗效与 STAT3 通路抑制 https://news.medxy.ai/ja/bendamustine-stat3-leukemia/Medxy AIja2026-09-18T11:00:24-07:00高腫瘍量T細胞大型顆粒リンパ球性白血病に対するBendamustine単剤療法：臨床効果とSTAT3経路阻害 https://news.medxy.ai/vi/bendamustine-treatment/Medxy AIvi2026-09-18T10:59:55-07:00Bendamustine: hướng điều trị đơn trị liệu mới đầy triển vọng cho T-cell large granular lymphocytic leukemia gánh nặng cao https://news.medxy.ai/bendamustine-as-a-novel-single-agent-therapy-in-high-burden-t-cell-large-granular-lymphocytic-leukemia-clinical-efficacy-and-stat3-pathway-inhibition/Medxy AIen2026-09-18T10:59:37-07:00Bendamustine as a Novel Single-Agent Therapy in High Burden T-Cell Large Granular Lymphocytic Leukemia: Clinical Efficacy and STAT3 Pathway Inhibition https://news.medxy.ai/zh/functional-immune-typing-prediction/Medxy AIzh2026-09-18T10:58:40-07:00用功能性免疫分型预测多发性骨髓瘤免疫治疗应答 https://news.medxy.ai/ja/multiple-myeloma-immunotherapy/Medxy AIja2026-09-18T10:58:13-07:00多発性骨髄腫免疫療法の応答予測に挑む機能的免疫プロファイリング https://news.medxy.ai/vi/immunotherapy-response-prediction/Medxy AIvi2026-09-18T10:57:44-07:00Khai thác phân tích miễn dịch chức năng để dự đoán đáp ứng trong miễn dịch trị liệu đa u tủy xương https://news.medxy.ai/leveraging-functional-immune-profiling-to-predict-response-in-myeloma-immunotherapy/Medxy AIen2026-09-18T10:57:23-07:00Leveraging Functional Immune Profiling to Predict Response in Myeloma Immunotherapy https://news.medxy.ai/zh/xmab18968-therapy-aml-tall/Medxy AIzh2026-09-18T10:56:38-07:00靶向 CD38 的创新双特异性抗体 XmAb18968：复发/难治性 AML 与 T-ALL 的治疗新希望 https://news.medxy.ai/ja/74865-2/Medxy AIja2026-09-18T10:56:20-07:00XmAb18968：再発・難治性AMLおよびT-ALL治療の新たな希望 https://news.medxy.ai/vi/74864-2/Medxy AIvi2026-09-18T10:55:53-07:00XmAb18968: Hy vọng mới trong điều trị AML và T-ALL tái phát/kháng trị https://news.medxy.ai/innovative-cd38-targeted-bispecific-antibody-xmab18968-shows-promise-in-relapsed-refractory-aml-and-t-all/Medxy AIen2026-09-18T10:55:31-07:00Innovative CD38-Targeted Bispecific Antibody XmAb18968 Shows Promise in Relapsed/Refractory AML and T-ALL https://news.medxy.ai/zh/lisocabtagene-survival-2/Medxy AIzh2026-09-18T10:54:31-07:00Lisocabtagene maraleucel在复发/难治性大B细胞淋巴瘤中的5年生存与持久缓解：TRANSCEND NHL 001研究启示 https://news.medxy.ai/ja/liso-cel-survival-transcend/Medxy AIja2026-09-18T10:54:07-07:00再発・難治性大細胞型B細胞リンパ腫におけるliso-celの5年生存と持続寛解：TRANSCEND NHL 001試験からの知見 https://news.medxy.ai/vi/lisocabtagene-survival/Medxy AIvi2026-09-18T10:53:48-07:00Lisocabtagene maraleucel mang lại sống còn 5 năm và lui bệnh bền vững trong u lympho tế bào B lớn tái phát/kháng trị: Góc nhìn từ nghiên cứu TRANSCEND NHL 001 https://news.medxy.ai/five-year-survival-and-durable-remission-with-lisocabtagene-maraleucel-in-relapsed-refractory-large-b-cell-lymphoma-insights-from-the-transcend-nhl-001-study/Medxy AIen2026-09-18T10:53:29-07:00Five-Year Survival and Durable Remission with Lisocabtagene Maraleucel in Relapsed/Refractory Large B-Cell Lymphoma: Insights from the TRANSCEND NHL 001 Study https://news.medxy.ai/zh/car-t-nfkb-myeloma/Medxy AIzh2026-09-17T10:52:36-07:00CAR-T 细胞中 NF-κB 驱动的转录特征可预测多发性骨髓瘤的持久应答 https://news.medxy.ai/ja/car-t-nf-kb-myeloma/Medxy AIja2026-09-17T10:52:07-07:00CAR-T細胞のNF-κB転写シグネチャが多発性骨髄腫における持続的奏効を予測する https://news.medxy.ai/vi/nfkb-car-t-response/Medxy AIvi2026-09-17T10:51:36-07:00Dấu ấn phiên mã do NF-κB điều khiển trong tế bào CAR-T dự báo đáp ứng bền vững ở đa u tủy xương https://news.medxy.ai/nfkb-car-t-signatures/Medxy AIen2026-09-17T10:51:03-07:00NF-κB Driven Transcriptional Signatures in CAR-T Cells Predict Durable Responses in Multiple Myeloma https://news.medxy.ai/zh/right-ventricle-mri/Medxy AIzh2026-09-17T10:50:05-07:00肺动脉高压中右心室评估的优化：后处理技术对心脏MRI指标的影响 https://news.medxy.ai/ja/right-ventricle-evaluation/Medxy AIja2026-09-17T10:49:39-07:00肺高血圧における右心室評価を磨く：ポストプロセッシング手法が心臓MRI指標に与える影響 https://news.medxy.ai/vi/optimization-right-ventricle-assessment/Medxy AIvi2026-09-17T10:49:05-07:00Tối ưu hóa đánh giá thất phải trong tăng áp động mạch phổi: Tác động của kỹ thuật xử lý hậu kỳ lên các chỉ số MRI tim https://news.medxy.ai/refining-right-ventricular-assessment-in-pulmonary-hypertension-impact-of-postprocessing-techniques-on-cardiac-mri-metrics/Medxy AIen2026-09-17T10:48:43-07:00Refining Right Ventricular Assessment in Pulmonary Hypertension: Impact of Postprocessing Techniques on Cardiac MRI Metrics https://news.medxy.ai/zh/infant-breathing-disorder/Medxy AIzh2026-09-17T10:47:50-07:00破解婴儿持续性呼吸急促之谜：遗传学新发现拓展诊断思路 https://news.medxy.ai/ja/persistent-tachypnea-in-infants/Medxy AIja2026-09-17T10:47:24-07:00乳児持続性多呼吸の正体に迫る：遺伝学的知見が診断の枠組みを広げる https://news.medxy.ai/vi/prolonged-rapid-breathing-infants/Medxy AIvi2026-09-17T10:46:56-07:00Giải mã thở nhanh kéo dài ở trẻ nhũ nhi: các phát hiện di truyền mở rộng mô hình chẩn đoán https://news.medxy.ai/decoding-persistent-tachypnea-of-infancy-genetic-insights-expand-diagnostic-paradigms/Medxy AIen2026-09-17T10:46:34-07:00Decoding Persistent Tachypnea of Infancy: Genetic Insights Expand Diagnostic Paradigms https://news.medxy.ai/zh/mechanical-ventilation-neutrophil-evs/Medxy AIzh2026-09-17T10:45:39-07:00机械通气诱导中性粒细胞细胞外囊泡：术后肺部并发症的新型介质 https://news.medxy.ai/ja/neutrophil-extracellular-vesicles/Medxy AIja2026-09-17T10:45:20-07:00機械的人工換気で誘導される好中球由来細胞外小胞：術後肺合併症における新たな媒介因子 https://news.medxy.ai/vi/mechanical-ventilation-exosomes/Medxy AIvi2026-09-17T10:44:52-07:00Túi ngoại bào từ bạch cầu trung tính do thông khí cơ học: chất trung gian mới trong biến chứng phổi sau phẫu thuật https://news.medxy.ai/mechanical-ventilation-induced-neutrophil-extracellular-vesicles-a-novel-mediator-in-postoperative-pulmonary-complications/Medxy AIen2026-09-17T10:44:30-07:00Mechanical Ventilation-Induced Neutrophil Extracellular Vesicles: A Novel Mediator in Postoperative Pulmonary Complications https://news.medxy.ai/zh/brazil-blood-transcriptome/Medxy AIzh2026-09-17T10:43:30-07:00巴西队列揭示：血液转录组特征可预测药物敏感性肺结核的不良结局 https://news.medxy.ai/ja/tb-blood-signature/Medxy AIja2026-09-17T10:43:05-07:00薬剤感受性肺結核における不良転帰予測因子としての血液トランスクリプトームシグネチャー：ブラジルコホートからの知見 https://news.medxy.ai/vi/blood-transcriptomics-prediction/Medxy AIvi2026-09-17T10:42:39-07:00Chữ ký transcriptomics máu dự báo kết cục xấu ở lao phổi nhạy cảm với thuốc: bằng chứng từ một đoàn hệ Brazil https://news.medxy.ai/blood-transcriptomic-signatures-as-predictors-of-poor-outcomes-in-drug-susceptible-pulmonary-tuberculosis-insights-from-a-brazilian-cohort/Medxy AIen2026-09-17T10:42:18-07:00Blood Transcriptomic Signatures as Predictors of Poor Outcomes in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Brazilian Cohort https://news.medxy.ai/zh/pegcetacoplan-macular-atrophy/Medxy AIzh2026-09-17T10:38:54-07:00玻璃体内 pegcetacoplan 治疗地图样萎缩：两年真实世界临床结局 https://news.medxy.ai/ja/74800-2/Medxy AIja2026-09-17T10:38:30-07:00地図状萎縮に対するペグセタコプラン硝子体内投与：2年間の実臨床における転帰 https://news.medxy.ai/vi/pegcetacoplan-geographic-atrophy/Medxy AIvi2026-09-17T10:38:00-07:00Kết quả sau hai năm của pegcetacoplan tiêm nội nhãn trong kiểm soát teo hoàng điểm địa lý: Kinh nghiệm lâm sàng thực tế https://news.medxy.ai/two-year-outcomes-of-intravitreal-pegcetacoplan-in-managing-geographic-atrophy-real-world-clinical-experience/Medxy AIen2026-09-17T10:37:39-07:00Two-Year Outcomes of Intravitreal Pegcetacoplan in Managing Geographic Atrophy: Real-World Clinical Experience https://news.medxy.ai/zh/trabeculectomy-failure-outcomes/Medxy AIzh2026-09-17T10:36:51-07:00小梁切除术失败眼的长期视野结局：重复小梁切除术与 Ahmed 青光眼阀植入术的比较 https://news.medxy.ai/ja/74792-2/Medxy AIja2026-09-17T10:36:29-07:00線維柱帯切除術後の長期成績：再線維柱帯切除術とAhmed緑内障バルブ埋め込み術の比較 https://news.medxy.ai/vi/long-term-glaucoma-results/Medxy AIvi2026-09-17T10:36:03-07:00Kết quả thị trường dài hạn ở mắt thất bại sau cắt bè củng mạc: So sánh cắt bè củng mạc lại với đặt van glaucoma Ahmed https://news.medxy.ai/long-term-visual-field-outcomes-in-eyes-with-failed-trabeculectomy-evaluating-repeat-trabeculectomy-versus-ahmed-glaucoma-valve-implantation/Medxy AIen2026-09-17T10:35:43-07:00Long-Term Visual Field Outcomes in Eyes with Failed Trabeculectomy: Evaluating Repeat Trabeculectomy versus Ahmed Glaucoma Valve Implantation https://news.medxy.ai/zh/pirfenidone-glottic-stenosis/Medxy AIzh2026-09-17T10:34:37-07:00大鼠模型中局部与全身吡非尼酮预防声门狭窄的比较评估 https://news.medxy.ai/ja/pirfenidone-administration-comparison/Medxy AIja2026-09-17T10:34:09-07:00ラット声門狭窄モデルにおけるピルフェニドン局所投与と全身投与の比較評価 https://news.medxy.ai/vi/pirfenidone-comparison/Medxy AIvi2026-09-17T10:33:33-07:00So sánh pirfenidone tại chỗ và toàn thân trong phòng ngừa hẹp thanh môn trên mô hình chuột cống https://news.medxy.ai/comparative-evaluation-of-topical-versus-systemic-pirfenidone-for-prevention-of-glottic-stenosis-in-a-rat-model/Medxy AIen2026-09-17T10:33:10-07:00Comparative Evaluation of Topical versus Systemic Pirfenidone for Prevention of Glottic Stenosis in a Rat Model https://news.medxy.ai/zh/angiography-post-pancreaticoduodenectomy/Medxy AIzh2026-09-17T10:32:09-07:00重新审视血管造影在胰十二指肠切除术后腔内出血诊断与处理中的作用：基于3,011例手术中115例病例的启示 https://news.medxy.ai/ja/post-pancreaticoduodenectomy-angiography/Medxy AIja2026-09-17T10:31:42-07:00膵頭十二指腸切除術後管腔内出血の診断と治療における血管造影の再評価：3,011例中115例の解析から https://news.medxy.ai/vi/angiography-role-gastrointestinal-bleeding/Medxy AIvi2026-09-17T10:31:13-07:00Chụp mạch có còn giữ vai trò trung tâm trong chẩn đoán và xử trí chảy máu trong lòng ống tiêu hóa sau phẫu thuật cắt tụy – tá tràng? Bằng chứng từ 115 ca trong 3.011 cuộc mổ https://news.medxy.ai/reevaluating-angiography-in-the-diagnosis-and-management-of-intraluminal-hemorrhage-following-pancreatoduodenectomy-insights-from-115-cases-among-3011-surgeries/Medxy AIen2026-09-17T10:30:51-07:00Reevaluating Angiography in the Diagnosis and Management of Intraluminal Hemorrhage Following Pancreatoduodenectomy: Insights from 115 Cases Among 3,011 Surgeries https://news.medxy.ai/zh/radioiodine-treatment-review/Medxy AIzh2026-09-17T10:29:58-07:00T3b分化型甲状腺癌中是否应重新审视放射性碘治疗？——基于SEER队列研究的启示 https://news.medxy.ai/ja/radioactive-iodine-therapy/Medxy AIja2026-09-17T10:29:34-07:00T3b分化型甲状腺癌における放射性ヨウ素療法を再検討する：SEERコホート研究からの知見 https://news.medxy.ai/vi/74764-2/Medxy AIvi2026-09-17T10:29:13-07:00Xem xét lại liệu pháp i-ốt phóng xạ đối với ung thư tuyến giáp biệt hóa giai đoạn T3b https://news.medxy.ai/reevaluating-radioactive-iodine-therapy-in-t3b-differentiated-thyroid-cancer-insights-from-a-seer-based-cohort-study/Medxy AIen2026-09-17T10:28:49-07:00Reevaluating Radioactive Iodine Therapy in T3b Differentiated Thyroid Cancer: Insights from a SEER-Based Cohort Study https://news.medxy.ai/zh/multidisciplinary-rehab/Medxy AIzh2026-09-17T10:27:45-07:00多学科康复助力生存者恢复：上消化道癌症术后患者心肺适能显著提升 https://news.medxy.ai/ja/upper-gastrointestinal-cancer-recovery/Medxy AIja2026-09-17T10:27:24-07:00上部消化管癌手術後の回復を支える：多職種リハビリテーションで心肺機能が改善 https://news.medxy.ai/vi/post-cancer-recovery/Medxy AIvi2026-09-17T10:26:56-07:00Tăng cường hồi phục sau ung thư: Phục hồi chức năng đa chuyên khoa giúp cải thiện thể lực tim phổi ở bệnh nhân sau phẫu thuật ung thư đường tiêu hóa trên https://news.medxy.ai/enhancing-survivorship-multidisciplinary-rehabilitation-improves-cardiorespiratory-fitness-in-upper-gastrointestinal-cancer-surgery-patients/Medxy AIen2026-09-17T10:26:32-07:00Enhancing Survivorship: Multidisciplinary Rehabilitation Improves Cardiorespiratory Fitness in Upper Gastrointestinal Cancer Surgery Patients https://news.medxy.ai/zh/femoral-artery-revascularization/Medxy AIzh2026-09-17T10:25:45-07:00股腘动脉病变所致跛行：血管内与外科血运重建结局的比较——来自 Medicare 关联数据的启示 https://news.medxy.ai/ja/74747-2/Medxy AIja2026-09-17T10:25:22-07:00大腿膝窩動脈病変による跛行：血管内治療と外科的血行再建術の転帰の比較 https://news.medxy.ai/vi/femoropopliteal-revascularization/Medxy AIvi2026-09-17T10:24:48-07:00So sánh kết cục tái tưới máu nội mạch và phẫu thuật ở bệnh động mạch đùi-khoeo gây đau cách hồi: Dữ liệu liên kết Medicare cho thấy điều gì? https://news.medxy.ai/comparing-endovascular-and-surgical-revascularization-outcomes-in-claudication-due-to-femoropopliteal-disease-insights-from-medicare-linked-data/Medxy AIen2026-09-17T10:24:25-07:00Comparing Endovascular and Surgical Revascularization Outcomes in Claudication Due to Femoropopliteal Disease: Insights from Medicare-Linked Data https://news.medxy.ai/zh/pregnancy-hpa-1a-immunity/Medxy AIzh2026-09-17T10:23:15-07:00妊娠期 HPA-1a 同种免疫化知多少：来自一项多族裔前瞻性研究的启示 https://news.medxy.ai/ja/hpa-1a-immunization-pregnancy/Medxy AIja2026-09-17T10:22:49-07:00妊娠中の HPA-1a 同種免疫化を読み解く：多民族前向き研究から得られた知見 https://news.medxy.ai/vi/alloimmunisation-hpa-1a-pregnancy/Medxy AIvi2026-09-17T10:22:26-07:00Alloimmunisation HPA-1a trong thai kỳ: Góc nhìn từ một nghiên cứu tiền cứu đa sắc tộc https://news.medxy.ai/understanding-hpa-1a-alloimmunisation-in-pregnancy-insights-from-a-multi-ethnic-prospective-study/Medxy AIen2026-09-17T10:22:05-07:00Understanding HPA-1a Alloimmunisation in Pregnancy: Insights from a Multi-Ethnic Prospective Study https://news.medxy.ai/zh/key-risk-factors-wound-complications/Medxy AIzh2026-09-17T10:21:14-07:00二度裂伤与会阴侧切术后伤口并发症的关键危险因素：REPAIR 研究带来的启示 https://news.medxy.ai/ja/perineal-wound-risks/Medxy AIja2026-09-17T10:20:45-07:00第2度裂傷・会陰切開後の会陰創傷合併症リスク因子を探る：REPAIR研究の二次解析から https://news.medxy.ai/vi/74724-2/Medxy AIvi2026-09-17T10:20:22-07:00Vết rách độ 2 là yếu tố nguy cơ chính dẫn đến các biến chứng vết thương sau thủ thuật cắt tầng sinh môn đường bên https://news.medxy.ai/identifying-key-risk-factors-for-perineal-wound-complications-after-second-degree-tears-and-episiotomy-insights-from-the-repair-study/Medxy AIen2026-09-17T10:20:01-07:00Identifying Key Risk Factors for Perineal Wound Complications After Second-Degree Tears and Episiotomy: Insights from the REPAIR Study https://news.medxy.ai/zh/trogocytosis-cldn18-2-cd8-tcells/Medxy AIzh2026-09-17T10:19:01-07:00Trogocytosis 介导的 CLDN18.2 获得削弱 CD8+ T 细胞抗肿瘤免疫并驱动胰腺癌进展 https://news.medxy.ai/ja/cldn18-2-trogocytosis-2/Medxy AIja2026-09-17T10:18:37-07:00trogocytosis により獲得された CLDN18.2 は CD8+ T 細胞の抗腫瘍免疫を損ない、膵癌進行を促進する https://news.medxy.ai/vi/cldn18-2-trogocytosis/Medxy AIvi2026-09-17T10:18:12-07:00CLDN18.2 do tế bào T CD8+ ‘mặc lên’ qua trogocytosis làm suy giảm miễn dịch chống u và thúc đẩy tiến triển ung thư tụy https://news.medxy.ai/trogocytosis-mediated-cldn18-2-acquisition-by-cd8-t-cells-impairs-anti-tumor-immunity-and-drives-pancreatic-cancer-progression/Medxy AIen2026-09-17T10:17:49-07:00Trogocytosis-Mediated CLDN18.2 Acquisition by CD8+ T Cells Impairs Anti-Tumor Immunity and Drives Pancreatic Cancer Progression https://news.medxy.ai/zh/parental-obesity-fatty-liver-risk/Medxy AIzh2026-09-17T10:16:44-07:00父母肥胖如何影响子代脂肪性肝病风险？英国出生队列研究给出新证据 https://news.medxy.ai/ja/parental-obesity-masld-risk-2/Medxy AIja2026-09-17T10:16:22-07:00両親の肥満は成人した子どものMASLDリスクを高める：英国出生コホート研究から見えたこと https://news.medxy.ai/vi/parental-obesity-masld-risk/Medxy AIvi2026-09-17T10:15:54-07:00Béo phì của bố mẹ làm tăng nguy cơ MASLD ở con trưởng thành: góc nhìn từ nghiên cứu đoàn hệ sinh tại Anh https://news.medxy.ai/parental-obesity-and-the-adult-offsprings-risk-of-metabolic-dysfunction-associated-steatotic-liver-disease-insights-from-a-uk-birth-cohort-study/Medxy AIen2026-09-17T10:15:31-07:00Parental Obesity and the Adult Offspring’s Risk of Metabolic Dysfunction Associated Steatotic Liver Disease: Insights from a UK Birth Cohort Study https://news.medxy.ai/zh/stroke-risk-carotid-stenosis-2/Medxy AIzh2026-09-17T10:14:24-07:00无症状颈动脉狭窄的卒中风险评估：经颈动脉血运重建与颈动脉支架植入术的比较 https://news.medxy.ai/ja/stroke-risk-carotid-stenosis-3/Medxy AIja2026-09-17T10:14:02-07:00無症候性頸動脈狭窄における脳卒中リスクの評価：経頸動脈血行再建術と頸動脈ステント留置術の比較 https://news.medxy.ai/vi/stroke-risk-carotid-stenosis/Medxy AIvi2026-09-17T10:13:33-07:00Đánh giá nguy cơ đột quỵ ở hẹp động mạch cảnh không triệu chứng: Tái thông động mạch cảnh qua đường xuyên cổ so với đặt stent động mạch cảnh https://news.medxy.ai/evaluating-stroke-risk-in-asymptomatic-carotid-stenosis-transcarotid-artery-revascularization-versus-carotid-artery-stenting/Medxy AIen2026-09-17T10:13:13-07:00Evaluating Stroke Risk in Asymptomatic Carotid Stenosis: Transcarotid Artery Revascularization versus Carotid Artery Stenting https://news.medxy.ai/zh/vascular-risk-brain-aging-2/Medxy AIzh2026-09-17T10:12:28-07:00早年血管风险与中年脑老化标志：来自纵向神经影像与认知轨迹研究的启示 https://news.medxy.ai/ja/vascular-risk-brain-aging/Medxy AIja2026-09-17T10:12:08-07:00若年期の血管リスクが中年期の脳老化に及ぼす影響：縦断的神経画像研究と認知軌跡研究からの知見 https://news.medxy.ai/vi/vascular-risk-aging-brain/Medxy AIvi2026-09-17T10:11:47-07:00Nguy cơ mạch máu từ sớm và các dấu ấn lão hóa não ở tuổi trung niên: Góc nhìn từ nghiên cứu chụp ảnh thần kinh theo dõi dọc và quỹ đạo nhận thức https://news.medxy.ai/early-life-vascular-risk-and-midlife-markers-of-brain-aging-insights-from-longitudinal-neuroimaging-and-cognitive-trajectory-studies/Medxy AIen2026-09-17T10:11:26-07:00Early Life Vascular Risk and Midlife Markers of Brain Aging: Insights from Longitudinal Neuroimaging and Cognitive Trajectory Studies https://news.medxy.ai/zh/diabetes-amputation-mortality/Medxy AIzh2026-09-17T09:56:42-07:00糖尿病膝下截肢后的死亡与致残：一项英格兰25年队列研究的启示 https://news.medxy.ai/ja/74622-2/Medxy AIja2026-09-17T09:56:23-07:00糖尿病患者における膝下切断後の死亡と障害：英国における25年間のコホート研究 https://news.medxy.ai/vi/below-knee-amputation-diabetes/Medxy AIvi2026-09-17T09:55:59-07:00Sau cắt cụt cẳng chân dưới gối ở người bệnh đái tháo đường: tử vong, biến chứng và nguy cơ kéo dài trong 25 năm https://news.medxy.ai/mortality-and-morbidity-after-below-knee-amputation-in-diabetes-insights-from-a-25-year-english-cohort-study/Medxy AIen2026-09-17T09:55:39-07:00Mortality and Morbidity After Below-Knee Amputation in Diabetes: Insights from a 25-Year English Cohort Study https://news.medxy.ai/zh/sarcoidosis-insights-2/Medxy AIzh2026-09-17T09:54:48-07:00心脏结节病新启示：MYSTICS 全国登记研究揭示诊断、治疗与预后的关键差异 https://news.medxy.ai/ja/74609-2/Medxy AIja2026-09-17T09:54:28-07:00心臓サルコイドーシスの診断・治療・予後における重要な相違点 https://news.medxy.ai/vi/sarcoidosis-insights/Medxy AIvi2026-09-17T09:54:07-07:00Sarcoidosis tim: Những hiểu biết toàn quốc từ cơ sở dữ liệu MYSTICS về chẩn đoán, điều trị và kết cục https://news.medxy.ai/cardiac-sarcoidosis-nationwide-insights-into-diagnosis-management-and-outcomes-from-the-mystics-registry/Medxy AIen2026-09-17T09:53:45-07:00Cardiac Sarcoidosis: Nationwide Insights into Diagnosis, Management, and Outcomes from the MYSTICS Registry https://news.medxy.ai/zh/targeted-vitamin-d/Medxy AIzh2026-09-17T09:52:58-07:00靶向维生素D补充用于心肌梗死后：来自TARGET-D试验的启示 https://news.medxy.ai/ja/targeted-vitamin-d-post-mi/Medxy AIja2026-09-17T09:52:42-07:00心筋梗塞後の標的型ビタミンD補充をどう評価するか：TARGET-D試験からの示唆 https://news.medxy.ai/vi/target-d-vitamin/Medxy AIvi2026-09-17T09:52:20-07:00Bổ sung vitamin D theo mục tiêu sau nhồi máu cơ tim: Những phát hiện từ thử nghiệm TARGET-D https://news.medxy.ai/evaluating-targeted-vitamin-d-supplementation-post-myocardial-infarction-insights-from-the-target-d-trial/Medxy AIen2026-09-17T09:52:02-07:00Evaluating Targeted Vitamin D Supplementation Post-Myocardial Infarction: Insights from the TARGET-D Trial https://news.medxy.ai/zh/heart-failure-cardiomyopathy/Medxy AIzh2026-09-17T09:51:07-07:00心力衰竭与心肌病中循证医学与个体化医疗的衔接：在标准化与个体化之间寻求平衡 https://news.medxy.ai/ja/ebm-personalized-care/Medxy AIja2026-09-17T09:50:45-07:00心不全・心筋症診療におけるEBMと個別化医療の架け橋：標準化と個別化の最適なバランス https://news.medxy.ai/vi/evidence-based-care-heart-failure/Medxy AIvi2026-09-17T09:50:19-07:00Dung hòa y học dựa trên bằng chứng và y học cá thể hóa trong suy tim và bệnh cơ tim: Cân bằng giữa chuẩn hóa và cá thể hóa https://news.medxy.ai/bridging-evidence-based-and-personalized-medicine-in-heart-failure-and-cardiomyopathies-balancing-standardization-with-individualization/Medxy AIen2026-09-17T09:49:55-07:00Bridging Evidence-Based and Personalized Medicine in Heart Failure and Cardiomyopathies: Balancing Standardization with Individualization https://news.medxy.ai/zh/acute-coronary-syndrome-pathways/Medxy AIzh2026-09-17T09:49:11-07:00真实世界中疑似急性冠脉综合征的0/1小时与0/3小时高敏肌钙蛋白路径比较 https://news.medxy.ai/ja/acute-coronary-syndrome-strategies/Medxy AIja2026-09-17T09:48:52-07:00実臨床で検証した：急性冠症候群疑いに対する0/1時間と0/3時間の高感度トロポニン戦略の比較 https://news.medxy.ai/vi/troponin-timing-comparison/Medxy AIvi2026-09-17T09:48:33-07:000/1 giờ hay 0/3 giờ: so sánh các đường đi troponin độ nhạy cao trong thực hành thực tế ở người bệnh nghi hội chứng vành cấp https://news.medxy.ai/comparing-0-1-hour-vs-0-3-hour-high-sensitivity-troponin-pathways-for-suspected-acute-coronary-syndrome-in-real-world-practice/Medxy AIen2026-09-17T09:48:08-07:00Comparing 0/1-Hour vs 0/3-Hour High-Sensitivity Troponin Pathways for Suspected Acute Coronary Syndrome in Real-World Practice https://news.medxy.ai/zh/bivalirudin-vs-heparin/Medxy AIzh2026-09-17T09:47:16-07:00BRIGHT-4 试验新解：Bivalirudin 与肝素在 STEMI 原发性 PCI 中的疗效比较及出血风险分层获益 https://news.medxy.ai/ja/74570-2/Medxy AIja2026-09-17T09:46:59-07:00STEMIに対する一次PCIにおけるビバリルジンとヘパリンの有効性比較 https://news.medxy.ai/vi/bright-4-pci-stemi/Medxy AIvi2026-09-17T09:46:39-07:00BRIGHT-4: Bivalirudin hay heparin trong PCI nguyên phát cho STEMI? Lợi ích trên cả nhóm nguy cơ chảy máu thấp và cao https://news.medxy.ai/bivalirudin-versus-heparin-in-primary-pci-for-stemi-efficacy-across-low-and-high-bleeding-risk-patients-insights-from-the-bright-4-trial/Medxy AIen2026-09-17T09:46:19-07:00Bivalirudin Versus Heparin in Primary PCI for STEMI: Efficacy Across Low and High Bleeding Risk Patients – Insights from the BRIGHT-4 Trial https://news.medxy.ai/zh/spaceflight-heart-adaptation/Medxy AIzh2026-09-17T09:45:19-07:00长期航天飞行与模拟火星重力下的心脏适应：一项纵向观察研究的启示 https://news.medxy.ai/ja/74565-2/Medxy AIja2026-09-17T09:44:58-07:00長期宇宙飛行および火星重力模擬環境下における心臓の適応 https://news.medxy.ai/vi/space-adaptation-mars-gravity/Medxy AIvi2026-09-17T09:44:32-07:00Tim thích nghi thế nào với bay vũ trụ dài ngày và trọng lực Sao Hỏa mô phỏng? Góc nhìn từ một nghiên cứu quan sát theo dõi dọc https://news.medxy.ai/cardiac-adaptations-to-prolonged-spaceflight-and-simulated-martian-gravity-insights-from-a-longitudinal-observational-study/Medxy AIen2026-09-17T09:44:11-07:00Cardiac Adaptations to Prolonged Spaceflight and Simulated Martian Gravity: Insights from a Longitudinal Observational Study https://news.medxy.ai/zh/gut-serotonin-vagus/Medxy AIzh2026-09-17T09:02:17-07:00肠道5-羟色胺能迷走神经信号：连接肠道菌群与高血压管理的新机制 https://news.medxy.ai/ja/serotonin-vagus-hypertension/Medxy AIja2026-09-17T09:01:55-07:00腸管セロトニン作動性迷走神経シグナル：腸内微生物叢と高血圧管理を結ぶ新たな架け橋 https://news.medxy.ai/vi/serotonergic-vagus-gut/Medxy AIvi2026-09-17T09:01:29-07:00Tín hiệu phế vị serotonergic ở ruột: mắt xích mới giữa hệ vi sinh đường ruột và kiểm soát tăng huyết áp https://news.medxy.ai/intestinal-serotonergic-vagal-signaling-a-novel-link-between-gut-microbiota-and-hypertension-management/Medxy AIen2026-09-17T09:01:08-07:00Intestinal Serotonergic Vagal Signaling: A Novel Link Between Gut Microbiota and Hypertension Management https://news.medxy.ai/zh/weight-loss-uric-acid-control/Medxy AIzh2026-09-17T07:36:21-07:00超重或肥胖男性高尿酸血症的减重与尿酸控制：限能量DASH、限碳水化合物与低嘌呤饮食的比较 https://news.medxy.ai/comparing-calorie-restricted-dash-carbohydrate-restricted-and-low-purine-diets-for-weight-loss-and-serum-urate-control-in-men-with-hyperuricemia/Medxy AIen2026-09-17T07:34:58-07:00Comparing Calorie-Restricted DASH, Carbohydrate-Restricted, and Low-Purine Diets for Weight Loss and Serum Urate Control in Men with Hyperuricemia